SCHEMBL14704875

SCHEMBL14704875

c1nnn(C2CC3CNCC3C2)n1

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21640781 0.82 MAPK1 (0.31) MAPK1HSD17B10
SCHEMBL14704880 0.75 CCR5 (0.35)
Hydrochloric Acid SCHEMBL8129255 0.72 MEN1 (0.32)
SCHEMBL14704874 0.65 HCAR2 (0.36)
SCHEMBL14704877 0.65 EPHX2 (0.32)
SCHEMBL9933548 0.65 SMN1; SMN2 (0.32)
Hydrochloric Acid SCHEMBL8433444 0.65 MAPK1 (0.32) MAPK1HSD17B10
SCHEMBL9933221 0.61 ELOVL1 (0.39)
SCHEMBL14704933 0.60 CCR5 (0.36)
SCHEMBL1338774 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190084982-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2019-03-21 US disclosed
EP-2742045-B1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2019-01-23 EP disclosed
US-20180105525-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2018-04-19 US disclosed
US-20180105525-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2018-04-19 US disclosed
US-9884864-B2 Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2018-02-06 US disclosed
US-9884864-B2 Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2018-02-06 US disclosed
US-20170174683-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2017-06-22 US disclosed
US-20170174683-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2017-06-22 US disclosed
US-9617262-B2 Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2017-04-11 US disclosed
US-9617262-B2 Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2017-04-11 US disclosed
US-20160194324-A1 ANTIBACTERIAL CYCLOPENTAL[C]PYRROLE SUBSTITUTED 3,4 DIHYDRO-1H-[1,8]NAPHTHYRIDINONES Janssen Sciences Ireland Unlimited Company (IE) 2016-07-07 US disclosed
US-9290493-B2 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2016-03-22 US disclosed
US-9290493-B2 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN SCIENCES IRELAND UC (IE) 2016-03-22 US disclosed
US-20150080413-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland Unlimited Company (IE) 2015-03-19 US disclosed
US-20150080413-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones Janssen Sciences Ireland Unlimited Company (IE) 2015-03-19 US disclosed
US-8906923-B2 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN R&D IRELAND (IE) 2014-12-09 US disclosed
US-8906923-B2 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN R&D IRELAND (IE) 2014-12-09 US disclosed
US-20140171451-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN R&D IRELAND (IE) 2014-06-19 US disclosed
US-20140171451-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones JANSSEN R&D IRELAND (IE) 2014-06-19 US disclosed
WO-2013021054-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES JANSSEN R&D IRELAND (IE) 2013-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084982-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES ECI1, ALPI, PREP MAPK1 2196/4885HSD17B10 487/4885
US-20150080413-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones ECI1, ALPI, PREP MAPK1 2196/4885HSD17B10 487/4885
US-20140171451-A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones ECI1, ALPI, PREP MAPK1 2196/4885HSD17B10 487/4885
US-20160194324-A1 ANTIBACTERIAL CYCLOPENTAL[C]PYRROLE SUBSTITUTED 3,4 DIHYDRO-1H-[1,8]NAPHTHYRIDINONES ECI1, ALPI, CYP51A1 MAPK1 1834/4885HSD17B10 389/4885
US-20170174683-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES ECI1, ALPI, PREP MAPK1 2196/4885HSD17B10 487/4885
US-20180105525-A1 ANTIBACTERIAL CYCLOPENTA[C]PYRROLE SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES ECI1, ALPI, PREP MAPK1 2196/4885HSD17B10 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.